Ind-Swift Laboratories Q1 FY27: PAT 2x, EBITDA 2.85x

Strong start to FY27 for Ind-Swift Laboratories

Ind-Swift Laboratories Ltd (INDSWFTLAB) reported a sharp improvement in profitability for the April to June 2026 quarter (Q1 FY27), supported by higher sales and margin expansion. The company said standalone profit after tax (PAT) excluding exceptional items rose 2.04 times year-on-year to ₹24.68 crore, compared with ₹8.12 crore in Q1 FY26. Operating EBITDA also increased 2.85 times year-on-year to ₹33.32 crore. The results were approved by the board on August 10, 2026, along with limited review reports from statutory auditors Rattan Kaur & Associates.

The company also pointed to progress on its contract development and manufacturing organisation (CDMO) pipeline and reiterated growth targets for FY27. Alongside the quarterly numbers, the board approved the sale of surplus land in Derabassi, Punjab, for ₹17.50 crore. Market updates cited different price points on the day: one disclosure referenced a current market price (CMP) of ₹237.24, up 3.87%, while another report said the stock surged 18.19% to ₹280.40.

Standalone performance: revenue up, margins expanded

On a standalone basis, revenue from operations for Q1 FY27 came in at ₹186.08 crore, up 21.16% year-on-year from ₹153.58 crore. Total income, including other income, rose to ₹193.71 crore from ₹162.58 crore. Profit before exceptional items and tax was reported at ₹32.66 crore.

Management highlighted that margin expansion was a key feature of the quarter. The operating EBITDA margin improved by 1,258 basis points year-on-year to 17.91%. PAT margin expanded by about 827 basis points to 13.26%, based on the company’s disclosure of PAT (excluding exceptional items). The update also referenced exceptional items of ₹0.24 crore (₹23.58 lakh) for the quarter.

Consolidated numbers: net sales and profit growth

On a consolidated basis, Ind-Swift Laboratories reported net sales of ₹191.45 crore in Q1 FY27, compared with ₹152 crore in Q1 FY26, a rise of 25.35% year-on-year. Consolidated adjusted net profit was reported at ₹24.86 crore, up 183.5% year-on-year and 28.9% quarter-on-quarter.

The company also reported consolidated profit before tax (PBT) of ₹32.56 crore, up 214.3% year-on-year and 172.2% quarter-on-quarter. Consolidated total income was disclosed as ₹199.11 crore (₹19,910.59 lakh). These metrics, taken together, indicate a quarter where both operating performance and profitability improved.

CDMO partnerships and product launches highlighted

Beyond the financial results, the company emphasised commercialisation activity tied to CDMO partnerships. It cited partnerships with Viatris (USA), Manx (UK), and Arrotex (Australia). According to the disclosure, these partnerships are expected to contribute ₹200-220 crore to FY27 revenue.

Ind-Swift also mentioned two new product launches across Europe and the UK/Australia regions. The updates framed these developments as part of the business mix improvement that supported margin expansion during the quarter.

FY27 outlook: revenue growth target and medium-term plan

The company stated a target of more than 50% revenue growth for FY27. It also indicated a medium-term revenue CAGR of 20-25% with margin expansion. These targets were presented as management expectations and were linked to CDMO scaling and improving operating efficiencies.

While the company did not provide a quarter-by-quarter roadmap in the shared details, the FY27 guidance was positioned as a continuation of the momentum seen in Q1 FY27. Investors typically track whether such targets are supported by order flows, product ramp-ups, and execution timelines.

Corporate action: sale of surplus land in Derabassi

The board approved the sale of approximately 40 bighas, or about 10 acres, of land at Village Behra, Derabassi, Punjab. The total consideration for the transaction is ₹17.50 crore. The company disclosed that the consideration is to be received over a period of nine months from the agreement date of August 10, 2026.

The buyers were disclosed as Nitin Jindal and others, and the company stated they are not related parties. Such transactions are often tracked for their impact on cash flows and balance sheet flexibility, although the quarter’s disclosures did not quantify a direct financial impact beyond the sale consideration and timing.

Key numbers at a glance

Market reaction and what investors tracked

The company’s disclosures included a CMP reference of ₹237.24, up 3.87%. Separately, a market report described the stock as having surged 18.19% to ₹280.40 after the results for the quarter ended June 30, 2026. The reported moves indicate heightened investor attention around the earnings and associated updates.

In this quarter, investors had multiple data points to evaluate: sales growth, operating profitability improvement, and management’s stated growth targets. The land sale approval also added a corporate action item that may be monitored for cash receipt progress over the stated nine-month period.

Why the quarter matters: margins and execution signals

The sharp rise in EBITDA and PAT, along with the margin expansion disclosed, signals improved operating leverage and business mix compared with the previous year’s quarter. The company’s emphasis on CDMO partnerships and commercialisation ties the quarter’s results to a longer runway, but the disclosures also specify that the expected contribution from key partnerships is tied to FY27.

The FY27 target of more than 50% revenue growth and the medium-term CAGR range of 20-25% set measurable benchmarks. For shareholders, subsequent quarters will likely be assessed against the pace of revenue additions from the named CDMO partners and the trajectory of margins from the Q1 FY27 base.

Conclusion

Ind-Swift Laboratories opened FY27 with higher standalone revenue, a steep year-on-year rise in EBITDA, and a more than two-fold increase in PAT excluding exceptional items. The company also announced a ₹17.50 crore land sale in Derabassi, with proceeds scheduled over nine months from August 10, 2026. Management’s FY27 growth target and the stated CDMO-linked revenue contribution will remain key reference points as the year progresses.